Journal of Preventive Medicine and Public Health

  • 제51권5호
  • /
  • Pages.257-262
  • /
  • 2018
  • /
  • 1975-8375(pISSN)
  • /
  • 2233-4521(eISSN)
대한예방의학회 (The Korean Society for Preventive Medicine)
권호 표지
DOI QR코드

DOI QR Code

National Trends in Smoking Cessation Medication Prescriptions for Smokers With Chronic Obstructive Pulmonary Disease in the United States, 2007-2012

  • Kwak, Min Ji (Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center at Houston) ;
  • Kim, Jongoh (Department of Medicine, Baylor College of Medicine) ;
  • Bhise, Viraj (Department of Management Policy and Community Health, University of Texas School of Public Health) ;
  • Chung, Tong Han (Healthcare Transformation Initiatives, McGovern Medical School, University of Texas Health Science Center at Houston) ;
  • Petitto, Gabriela Sanchez (Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center at Houston)
  • 투고 : 2018.05.25
  • 심사 : 2018.08.23
  • 발행 : 2018.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objectives: Smoking cessation decreases morbidity and mortality due to chronic obstructive pulmonary disease (COPD). Pharmacotherapy for smoking cessation is highly effective. However, the optimal prescription rate of smoking cessation medications among smokers with COPD has not been systemically studied. The purpose of this study was to estimate the national prescription rates of smoking cessation medications among smokers with COPD and to examine any disparities therein. Methods: We conducted a retrospective study using National Ambulatory Medical Care Survey data from 2007 to 2012. We estimated the national prescription rate for any smoking cessation medication (varenicline, bupropion, and nicotine replacement therapy) each year. Multiple survey logistic regression was performed to characterize the effects of demographic variables and comorbidities on prescriptions. Results: The average prescription rate of any smoking cessation medication over 5 years was 3.64%. The prescription rate declined each year, except for a slight increase in 2012: 9.91% in 2007, 4.47% in 2008, 2.42% in 2009, 1.88% in 2010, 1.46% in 2011, and 3.67% in 2012. Hispanic race and depression were associated with higher prescription rates (odds ratio [OR], 5.15; 95% confidence interval [CI], 1.59 to 16.67 and OR, 2.64; 95% CI, 1.26 to 5.51, respectively). There were no significant differences according to insurance, location of the physician, or other comorbidities. The high OR among Hispanic population and those with depression was driven by the high prescription rate of bupropion. Conclusions: The prescription rate of smoking cessation medications among smokers with COPD remained low throughout the study period. Further studies are necessary to identify barriers and to develop strategies to overcome them.

키워드

참고문헌

  1. World Health Organization. The top 10 causes of death; 2018 May 24 [cited 2018 Sep 10]. Available from: http://www.who.int/en/news-room/fact-sheets/detail/the-top-10-causes-of-death.
  2. National Heart, Lung, and Blood Institute. Morbidity and mortality: 2012 chart book on cardiovascular, lung and blood diseases; 2012 [cited 2018 Sep 10]. Available from: https://www.nhlbi.nih.gov/files/docs/research/2012_ChartBook_508.pdf.
  3. Raherison C, Girodet PO. Epidemiology of COPD. Eur Respir Rev 2009;18(114):213-221. https://doi.org/10.1183/09059180.00003609
  4. Dalal AA, Christensen L, Liu F, Riedel AA. Direct costs of chronic obstructive pulmonary disease among managed care patients. Int J Chron Obstruct Pulmon Dis 2010;5:341-349.
  5. Darnell K, Dwivedi AK, Weng Z, Panos RJ. Disproportionate utilization of healthcare resources among veterans with COPD: a retrospective analysis of factors associated with COPD healthcare cost. Cost Eff Resour Alloc 2013;11:13. https://doi.org/10.1186/1478-7547-11-13
  6. Crisafulli E, Costi S, Luppi F, Cirelli G, Cilione C, Coletti O, et al. Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation. Thorax 2008;63(6):487-492. https://doi.org/10.1136/thx.2007.086371
  7. Godtfredsen NS, Lam TH, Hansel TT, Leon ME, Gray N, Dresler C, et al. COPD-related morbidity and mortality after smoking cessation: status of the evidence. Eur Respir J 2008;32(4):844-853. https://doi.org/10.1183/09031936.00160007
  8. Tashkin DP, Rennard S, Hays JT, Ma W, Lawrence D, Lee TC. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest 2011; 139(3):591-599. https://doi.org/10.1378/chest.10-0865
  9. Rigotti NA, Munafo MR, Stead LF. Smoking cessation interventions for hospitalized smokers: a systematic review. Arch Intern Med 2008;168(18):1950-1960. https://doi.org/10.1001/archinte.168.18.1950
  10. Fiore MC, Jaen CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, et al. Treating tobacco use and dependence: 2008 update. Rockville: US Department of Health and Human Services. Public Health Service; 2008, 106-124.
  11. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 2013;(5):CD009329.
  12. Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 2016;387 (10037):2507-2520. https://doi.org/10.1016/S0140-6736(16)30272-0
  13. Tonnesen P. Smoking cessation and COPD. Eur Respir Rev 2013; 22(127):37-43. https://doi.org/10.1183/09059180.00007212
  14. Melzer AC, Feemster LC, Collins MP, Au DH. Predictors of pharmacotherapy for tobacco use among Veterans admitted for COPD: the role of disparities and tobacco control processes. J Gen Intern Med 2016;31(6):623-629. https://doi.org/10.1007/s11606-016-3623-4
  15. Vaidya V, Hufstader-Gabriel M, Gangan N, Shah S, Bechtol R. Utilization of smoking-cessation pharmacotherapy among chronic obstructive pulmonary disease (COPD) and lung cancer patients. Curr Med Res Opin 2014;30(6):1043-1050. https://doi.org/10.1185/03007995.2014.884493
  16. Jarlenski M, Hyon Baik S, Zhang Y. Trends in use of medications for smoking cessation in medicare, 2007-2012. Am J Prev Med 2016;51(3):301-308. https://doi.org/10.1016/j.amepre.2016.02.018
  17. Melzer AC, Feemster LC, Collins MP, Au DH. Utilization and effectiveness of pharmacotherapy for tobacco use following admission for exacerbation of COPD. J Hosp Med 2016;11(4): 257-263. https://doi.org/10.1002/jhm.2519
  18. Kim MJ, Jeong IS. Smoking relapse and related factors within one year among successes of the smoking cessation clinics of public health centers. J Prev Med Public Health 2011;44(2):84-92 (Korean). https://doi.org/10.3961/jpmph.2011.44.2.84
  19. Centers for Disease Control and Prevention. Ambulatory health care data [cited 2018 May 25]. Available from: https://www.cdc.gov/nchs/ahcd/index.htm.
  20. US Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA revises description of mental health side effects of the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) to reflect clinical trial findings; 2015 [cited 2018 May 25]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm532221.htm.

피인용 문헌

  1. Secular trends in smoking in relation to prevalent and incident smoking-related disease: A prospective population-based study vol.17, pp.10, 2018, https://doi.org/10.18332/tid/112459
  2. Polypharmacy among Older Individuals with COPD: Trends between 2000 and 2015 in Quebec, Canada vol.16, pp.3, 2018, https://doi.org/10.1080/15412555.2019.1646716
  3. Tobacco Screening and Treatment of Patients With a Psychiatric Diagnosis, 2012–2015 vol.57, pp.5, 2018, https://doi.org/10.1016/j.amepre.2019.06.009